TB006 for Autism Spectrum Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.
Epistemonikos ID: 591fa195bc5441aa9f63447dec6f5e72965d1ed1
First added on: Aug 01, 2024